Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novartis Ag ADR (NY: NVS )

109.35 +0.95 (+0.88%)
Official Closing Price Updated: 7:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novartis Ag ADR

< Previous 1 2
...
22 23 24 25 26 27 28 29 30
...
42 43 Next >
Antifungal Drugs Market Import-Export Details, Production Information 2022-2029 : Sanofi-Aventis, Novartis, Pfizer Inc, Abbott Laboratories
Global Antifungal Drugs Market Research 2022-2031 published by Calibre Research studies the current situation, Antifungal Drugs market size, share, trends, regional growth and the latest technologies... 
Via SBWire
Topics Supply Chain
Exposures Supply Chain
Celldex Therapeutics Skids As It Takes On A Blockbuster Roche, Novartis Drug
The study was in 26 patients with chronic hives that don't respond to antihistamines. 
Via Investor's Business Daily
Cough Remedies Market 2022-2029 Global Industry Trends, Growth Rate and Revenue : Pfizer, Johnson & Johnson, GlaxoSmithKline, Novartis
Global Cough Remedies Market Research 2022-2031 published by Calibre Research studies the current situation, Cough Remedies market size, share, trends, regional growth and the latest technologies... 
Via SBWire
Topics Supply Chain
Exposures Supply Chain
The Daily Biotech Pulse: Pfizer/BioNTech Ink New COVID-19 Vaccine Supply Pact, Sanofi Hit By FDA Clinical Hold, Angion Biomedica Halts Second Kidney Disease Trial
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Novartis Resumes Production, Delivery Of Radioligand Therapy Medicines
Via Benzinga
Novartis' Tislelizumab Extends Overall Survival In Late-Stage Esophageal Cancer Study
Novartis AG (NYSE: NVS) announced results from the Phase 3 RATIONALE 306 trial of tislelizumab plus chemotherapy in patients with unresectable, locally advanced recurrent or metastatic esophageal... 
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
Tigecycline Market Development Factors 2022-2029 Pfizer, Hisun Pharma, Hansoh Pharma, HICIN Pharma, Amgen
Global Tigecycline Market Research 2022-2031 published by Calibre Research studies the current situation, Tigecycline market size, share, trends, regional growth and the latest technologies utilized by... 
Via SBWire
Topics Supply Chain
Exposures Supply Chain
Novartis Announces $250M In R&D Funding For Neglected Tropical Diseases, Malaria
Via Benzinga
FDA Gives Approval For Novartis' Tafinlar + Mekinist Broadens BRAF/MEK Cancer Combo Use
Via Benzinga
Why Precision BioSciences Shares Are Surging Today
Via Benzinga
Global Interferon Beta Drugs Market | Key Players are Biogen, Merck, Novartis, Bayer, Faron Pharmaceuticals, and other prominent players
Global Interferon Beta Drugs Market | Key Players are Biogen, Merck, Novartis, Bayer, Faron Pharmaceuticals, and other prominent players The market size of the Global Interferon Beta Drugs Market in... 
Via iCrowdNewswire
Global Radioligand Therapy Market | Key Players are Johnson & Johnson Services, Inc., Pfizer Inc., Bayer AG, Molecular Partners, ITM Isotope Technologies Munich SE, Amneal Pharmaceuticals LLC, Novartis International AG and many more.
Global Radioligand Therapy Market | Key Players are Johnson & Johnson Services, Inc., Pfizer Inc., Bayer AG, Molecular Partners, ITM Isotope Technologies Munich SE, Amneal Pharmaceuticals LLC, Novartis... 
Via iCrowdNewswire
Precision BioSciences (DTIL) Stock Treks Higher on Novartis Deal
DTIL stock is advancing in early trading today after Precision BioScience announced a partnership with Novartis, a leading drug maker. 
Via InvestorPlace
The Daily Biotech Pulse: Precision BioSciences Inks Gene Editing Pact, Athira Pharma's Alzheimer's Candidate Fails, Enanta Sues Pfizer Over COVID-19 Antiviral
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
NYSE:NVS Investor Alert: Investigation over Possible Securities Laws Violations by Novartis AG
San Diego, CA -- (SBWIRE) -- 06/17/2022 -- Novartis AG is under investigation concerning potential securities laws violations in connection with certain financial statements. 
Via SBWire
Analysts Remain Bullish Despite Caribou's Allogeneic CAR-T Hit By Durability
Via Benzinga
Crews Control Names Barbara Kittridge President, Andrea Keating Moves to CEO
Crews Control promotes Barbara Kittridge to President. 
Via Newswire.com
Exposures COVID-19
Sylvester Feddes joins the 2022 Leading Entrepreneurs of the World Conference
The Country President of Novartis Colombia will speak at 1BusinessWorld’s Leading Entrepreneurs of the World Conference about leading diversity and inclusion in a virtual environment 
Via News Direct
Pfizer's Ibrance Fails To Extend Overall Survival In Newly Diagnosed Breast Cancer Setting
Via Benzinga
2021 R&D Spending and Intensity Benchmarks
VIRGINIA BEACH, Va. - June 6, 2022 - PRLog -- According to a newly released study from Schonfeld & Associates, Inc., R&D Ratios & Budgets, the pharmaceutical industry continued to be the biggest R&D... 
Via PRLog
Topics Supply Chain
Exposures Supply Chain
NOVARTIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Novartis AG on Behalf of Novartis Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
New effort to standardize cardiovascular care in Mexico, address gaps in care
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
NOVARTIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Novartis AG on Behalf of Novartis Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Novartis AG (NVS) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Novartis AG (NVS) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
The Law Offices of Frank R. Cruz Announces Investigation of Novartis AG (NVS) on Behalf of Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
Attention Biotech Investors: Mark Your Calendar For These June PDUFA Dates
May turned out to be a month of mixed fortunes as far as regulatory reviews are concerned. New molecular entity approvals, an indicator of innovation in drug research, totaled three during the month,... 
Via Benzinga
Global Central Nervous System Treatment Market Is Expected to Reach $166 Billion In 2028
Palm Beach, FL – May 26, 2022 – FinancialNewsMedia.com News Commentary – Worldwide, there is a rapid increase in the prevalence and incidence of neurological disorders such as multiple sclerosis,... 
Via FinancialNewsMedia
Exposures COVID-19
6 Dividend Stocks With High Yields and Low P/E Ratios
These 6 dividend stocks have yields greater than 2.5% and P/E ratios lower than 16x with a positive earnings growth forecast for 2023. 
Via InvestorPlace
< Previous 1 2
...
22 23 24 25 26 27 28 29 30
...
42 43 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.